<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054015</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269675</org_study_id>
    <secondary_id>VION-CLI-024</secondary_id>
    <secondary_id>MCC-13110</secondary_id>
    <secondary_id>MCC-IRB-100798</secondary_id>
    <nct_id>NCT00054015</nct_id>
  </id_info>
  <brief_title>3-AP in Treating Patients With Advanced Prostate Cancer</brief_title>
  <official_title>A Phase II Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Patients With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have&#xD;
      advanced prostate cancer that has been previously treated with hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with advanced hormone-refractory prostate cancer&#xD;
           treated with 3-AP.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 3-AP IV over 2 hours on days 1-4. Treatment repeats every 2 weeks for up to&#xD;
      1 year in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2-3 months for up to 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 13-27 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of hormone-refractory metastatic prostate cancer by one of the following&#xD;
             methods:&#xD;
&#xD;
               -  Measurable disease&#xD;
&#xD;
               -  PSA level of at least 5 ng/mL with a positive bone scan&#xD;
&#xD;
          -  Objective evidence of progressive metastatic disease in the past 3 months defined by&#xD;
             any of the following:&#xD;
&#xD;
               -  An increase in PSA value of at least 25% (minimum absolute increase of 5 ng/mL)&#xD;
                  on at least 2 successive occasions, at least 2 weeks apart&#xD;
&#xD;
               -  A new symptomatic lesion on bone scan&#xD;
&#xD;
               -  A new metastases not in bone&#xD;
&#xD;
               -  Growth of existing non-bone measurable metastatic disease NOTE: An increase in&#xD;
                  pain or symptoms alone without other evidence of progression, or elevation of PSA&#xD;
                  or serum alkaline phosphatase alone without evidence of metastatic disease is not&#xD;
                  sufficient&#xD;
&#xD;
          -  Prior bilateral orchiectomy or other primary hormonal treatment with evidence of&#xD;
             treatment failure&#xD;
&#xD;
               -  Patients with no prior bilateral orchiectomy must have a testosterone level less&#xD;
                  than 50 ng/mL and must continue leuteinizing hormone-releasing hormone therapy&#xD;
                  while on study&#xD;
&#xD;
          -  No known active CNS metastases (excluding prior CNS metastases with currently stable&#xD;
             disease after treatment )&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  ALT/AST no greater than 5 times upper limit of normal&#xD;
&#xD;
          -  Albumin greater than 2.5 g/dL&#xD;
&#xD;
          -  Chronic hepatitis allowed&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 3 months&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No uncontrolled arrhythmias&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No dyspnea at rest&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Nutrition adequate (caloric intake considered adequate for maintenance of weight)&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior or concurrent malignancies except for non-metastatic basal cell or squamous&#xD;
             cell skin cancer or any stage I malignancy curatively resected more than 5 years ago&#xD;
&#xD;
          -  No active uncontrolled infectious process&#xD;
&#xD;
          -  No other life-threatening illness&#xD;
&#xD;
          -  No peripheral neuropathy greater than grade 2&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 2 weeks since prior biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since other prior hormonal therapy including any of the following:&#xD;
&#xD;
               -  Megestrol&#xD;
&#xD;
               -  Finasteride&#xD;
&#xD;
               -  Herbal products known to decrease PSA levels (e.g., saw palmetto and PC-SPES)&#xD;
&#xD;
               -  Systemic corticosteroids&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide therapy (6 weeks for bicalutamide or&#xD;
             nilutamide) with continued evidence of progressive disease documented by at least 1&#xD;
             PSA value after discontinuation&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 8 weeks since prior radiopharmaceuticals (strontium chloride Sr 89, samarium&#xD;
             Sm 153 lexidronam pentasodium)&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Sznol, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vion Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>November 5, 2013</last_update_submitted>
  <last_update_submitted_qc>November 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

